Considering the current situation in the country and taking into account the needs of patients, Actero Company decided to spend all the costs related to the unveiling of the drug Bortezomib ACTe on the first free injection of patients’ candidates receiving Bortezomib. Therefore, by delivering the drug sample to physicians specializing in this field, treatment coverage began in a number of eligible patients.